These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. Canobbio L; Boccardo F; Cannata D; Gallotti P; Epis R Cancer; 1992 Feb; 69(3):648-50. PubMed ID: 1346097 [TBL] [Abstract][Full Text] [Related]
25. Palliative interventions in patients with peritoneal metastases and malignant bowel obstruction. Bellavance EC; Alexander HR J Clin Oncol; 2012 Dec; 30(35):4290-1. PubMed ID: 23109693 [No Abstract] [Full Text] [Related]
26. The effects of vapreotide, a somatostatin analogue, on gastric acidity, gallbladder emptying and hormone release after 1 week of continuous subcutaneous infusion in normal subjects. Ritz MA; Drewe J; Ziel A; Hildebrand P; Schneider P; Lahlou N; Beglinger C Br J Clin Pharmacol; 1999 Feb; 47(2):195-201. PubMed ID: 10190655 [TBL] [Abstract][Full Text] [Related]
27. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules. Zalatnai A; Schally AV Cancer Res; 1989 Apr; 49(7):1810-5. PubMed ID: 2564312 [TBL] [Abstract][Full Text] [Related]
28. Somatostatin analogs in the management of gastrointestinal tumors. Lamberts SW Horm Res; 1988; 29(2-3):118-20. PubMed ID: 2900191 [TBL] [Abstract][Full Text] [Related]
29. [Nausea is a common symptom in palliative care. Choice of treatment is based on the cause]. Strang P; Jakobsson M Lakartidningen; 1999 Apr; 96(14):1743-5. PubMed ID: 10222693 [TBL] [Abstract][Full Text] [Related]
30. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse. González-Barcena D; Schally AV; Vadillo-Buenfil M; Cortez-Morales A; Hernández L V; Cardenas-Cornejo I; Comaru-Schally AM Prostate; 2003 Aug; 56(3):183-91. PubMed ID: 12772187 [TBL] [Abstract][Full Text] [Related]
31. The palliative effects of octreotide in malignant disease. Dean A; Bridge D; Lickiss JN Ann Acad Med Singap; 1994 Mar; 23(2):212-5. PubMed ID: 7521613 [TBL] [Abstract][Full Text] [Related]
36. Paralytic ileus responding to somatostatin therapy: first manifestation of a VIPoma. Koberstein B; Layer P; Balzer K; Müller MK; Singer MV; Goebell H Dig Dis Sci; 1989 Nov; 34(11):1803-4. PubMed ID: 2573486 [No Abstract] [Full Text] [Related]
37. Glucagonoma syndrome: diagnosis and treatment. Zeng J; Wang B; Ma D; Li F J Am Acad Dermatol; 2003 Feb; 48(2):297-8. PubMed ID: 12582409 [No Abstract] [Full Text] [Related]
38. Somatostatin analogue SMS 201-995 long term therapy for vipoma. Juby LD; Burke DA; Axon AT Postgrad Med J; 1987 Apr; 63(738):287-9. PubMed ID: 2891127 [TBL] [Abstract][Full Text] [Related]
39. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. Phan AT; Kunz PL; Reidy-Lagunes DL Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956 [TBL] [Abstract][Full Text] [Related]
40. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Modlin IM; Pavel M; Kidd M; Gustafsson BI Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]